OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen.
Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.
The MET oncogene activated signalling pathway is known to be hyper-activated in identifiable subsets of a range of major cancer types. The MET receptor has recently been demonstrated to be a functional marker of cancer stem like cells that are responsible for the development of resistance to radiotherapy and a number of chemotherapy and targeted anti-cancer agents. Inhibition of the MET kinase signalling pathway has been demonstrated to block MET driven cancers and overcome MET induced resistance to a range of therapeutic agents leading, in some cases, to the cure of tumor bearing preclinical animals. OCTIMET have proprietary knowledge of pathways and targets that would result in rational combination therapeutic partners.
OMO-1 is a highly selective small molecule MET kinase inhibitor that has demonstrable single agent cellular and in vivo activity only in MET driven preclinical models as expected from a highly selective agent. OMO-1 has recently been explored in a healthy volunteer trial where predicted efficacious exposures were reached without any significant adverse events. Available dose and exposure correlations and optimal dosing regimes that were defined in this healthy volunteer trial will guide and expedite clinical evaluation in forthcoming patient trials.
The clean safety profile observed in the healthy volunteer trial needs to be confirmed in an accelerated Phase 1 dose escalation study carried out in non selected cancer patients followed by demonstrating evidence of clinical activity in a MET biomarker selected expansion cohort.
A Phase 2a study to confirm activity in MET biomarker selected population will generate proof of concept data to support a larger registration trial.
Innovative study design and timelines that are envisaged will allow OMO-1 to leapfrog competitors and achieve best in class status. Based on the high combination potential inherent to OMO-1 and known MET pharmacology, additional opportunities for significantly increasing market size exist in a range of indications with a defined set of evidence driven, biomarker selected, combination partners.
OMO-2 is a differentiated follow-up MET-inhibitor with similar high selectivity that is in late non-clinical development.
Images courtesy of Letizia Lanzetti - Membrane Trafficking Laboratory - Candiolo Cancer Institute- FPO, IRCCS - Torino (Italy)
OCTIMET Oncology NV, based at the JLINX facility in Beerse, Belgium, with a focus on the development of selective MET kinase inhibitory drug candidates, today announced it has received a €1.12 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, former IWT.
Beerse (Belgium), 7 November 2017 – OCTIMET Oncology NV, a translational accelerator, focusing on creating value for patients and investors by providing rapid clinical proof of concept for cancer therapies, through innovative clinical development strategies and patient centered biomarker approaches, announces that it has been awarded a €1.12 million industrial R&D Project Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by OCTIMET to generate further preclinical in vitro and in vivo data on innovative combination options with the lead compound OMO-1 and both novel and approved therapies. Work will be carried out in collaboration with expert CRO’s and academic partners including the VIB.
Beerse, Belgium August 29th 2017: OCTIMET Oncology NV, the Belgian life science company with a focus on the development of MET kinase inhibitory drug candidates having additional differentiating properties, is pleased to announce the dosing of OMO-1 to the first patient. The multicenter, Phase I/II clinical trial (NCT03138083) is primarily evaluating the safety, pharmacokinetics and tolerability, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.
OMO-1 is a selective small molecule that has demonstrated potent single agent and combination activity in a range of preclinical models. OCTIMET obtained a worldwide exclusive license to OMO-1 from Janssen Pharmaceutica who had previously carried out a healthy volunteer trial where predicted efficacious exposures were reached without any significant adverse events.
Beerse, Belgium January 19th 2017: OCTIMET Oncology NV (OCTIMET), has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the clinical development of clinically de-risked MET kinase inhibitors, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.
OCTIMET was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen FCA. Headed by Dr. Timothy Perera, OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based approaches, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents.